Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 5/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6427044 | 0.91 | TSHR (0.47) | ALDH1A1TSHRKDM4EHSD17B10L3MBTL1 | |
| SCHEMBL6503596 | 0.91 | TSHR (0.47) | ALDH1A1TSHRKDM4EHSD17B10L3MBTL1 | |
| SCHEMBL6427385 | 0.91 | TSHR (0.47) | ALDH1A1TSHRKDM4EHSD17B10L3MBTL1 | |
| SCHEMBL6428790 | 0.87 | HPGD (0.39) | ALDH1A1TSHRKDM4EHSD17B10MAPT | |
| SCHEMBL6429808 | 0.84 | ALDH1A1 (0.43) | ALDH1A1TSHRHIF1AKDM4EPKM | |
| SCHEMBL1605486 | 0.84 | ALDH1A1 (0.43) | ALDH1A1TSHRHIF1AKDM4EPKM | |
| SCHEMBL6426928 | 0.83 | TSHR (0.34) | ALDH1A1TSHR | |
| SCHEMBL1605522 | 0.81 | KDM4C (0.38) | ALDH1A1TSHRKDM4EMAPTL3MBTL1 | |
| SCHEMBL6427594 | 0.81 | TSHR (0.32) | TSHRCTSS | |
| SCHEMBL6428130 | 0.81 | KMT2A (0.49) | ALDH1A1HSD17B10TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | claimed |
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | disclosed |
| WO-2005075471-A2 | THIAZOL-COMPOUNDS AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | BIOVITRUM AB (SE) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239853-A1 | New compounds | HSD11B1, CYP11B1, HSD3B1 | ALDH1A1 67/4885TSHR 2078/4885HIF1A 1192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.